IPO - Profile


We are a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. We founded atai Life Sciences in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and digital therapeutics. We have built a pipeline of 10 development programs and six enabling technologies, each led by focused teams with deep expertise in their respective fields and supported by our More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$15.00 15,000,000 Positive High 58.49%

Offering Team

  • Legal counsel
  • Davis Polk & Wardwell LLP
  • Auditors
  • Deloitte & Touche LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 17 Jun, 2021

Offer 18 Jun, 2021

Look Ahead

Lock Up Expiry Dec 18, 2021

IPO Terms

Offer Price $15.00
Offer Size 15M

Market Sentiments

Stock Price